Oncology Institute (DFPH) Equity Average (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Equity Average data on file, last reported at -$16.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 469.66% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at -$16.0 million (down 469.66% YoY), and the FY2025 full-year result was -$6.1 million, down 120.01% from the prior year.
• Equity Average for Q1 2026 stood at -$16.0 million, down from -$14.0 million in the prior quarter.
• Across five years, Equity Average topped out at $128.0 million in Q2 2022 and bottomed at -$16.0 million in Q1 2026.
• The 5-year median for Equity Average is $49.2 million (2024), against an average of $54.2 million.
• The widest annual swing landed in 2022, when Equity Average jumped 213.84%; it then slumped 469.66% in 2026.
• A 5-year view of Equity Average shows it stood at $125.6 million in 2022, then tumbled by 48.68% to $64.4 million in 2023, then tumbled by 85.2% to $9.5 million in 2024, then plunged by 246.79% to -$14.0 million in 2025, then slipped by 14.33% to -$16.0 million in 2026.
• The last three Equity Average figures came in at -$16.0 million (Q1 2026), -$14.0 million (Q4 2025), and -$10.6 million (Q3 2025), per Business Quant data.

Peer Comparison